EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...
"LIVING WELL WITH CML" Are you or someone you know living with chronic myeloid leukemia (CML)? Join Novartis Oncology, along with The National CML Society and a panel of healthcare experts, for an ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix ...
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...
California will become the first state in the nation requiring restaurants to list major food allergens on their menus starting in 2026 under a new law. The law Gov. Gavin Newsom signed Monday applies ...
3d
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in ...
Basel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback